Osteoporosis Treatment Market to Reach USD 15.08 Billion by 2026; Increasing Clinical Trials and Better Diagnostic Solutions are Fueling Market Growth

The global osteoporosis treatment market size is projected to reach USD 15.08 billion by the end of 2026. Increasing clinical trials and better diagnostic solutions are anticipated to fuel the market growth during forecast period. According to a report published by Fortune Business Insights, titled “Osteoporosis Treatment Market Size, Share & Industry Analysis, By Drug Class (Bisphosphonate, Hormone Replacement Therapy, Selective Estrogen Receptor Modulator (SERMs), RANK ligand (RANKL) Inhibitor, and Others), By Route of Administration (Oral, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Stores, and Others), and Regional Forecast, 2019-2026,” the market size was USD 10.74 billion in 2018 and will exhibit a CAGR of 4.3% during the forecast period, 2019-2026.

Osteoporosis is a condition that causes thee bones to become brittle and porous. It reduces the bone density and minerals and exposes the body to fractures and minerals. The severity of the disease has created a high emphasis on the need for early detection and prevention. Moreover, the adverse effects of this condition have led to more attention on the research and development of efficient treatment options. As a result, high investments are made in the development of newer treatment options. The massive investments will have a direct impact on the growth of the overall market in the coming years. The high prevalence of osteoporosis across the world has created several growth opportunities for the companies operating in the market.

Amgen’s FDA Approval for Evenity Will Aid Growth

Recent scientific advances have allowed improved treatment options for osteoporosis. The increasing investment has massively helped develop efficient treatment options. The improvements in treatment options and lesser side effects associated with the same have encouraged regulatory bodies to approve more products and therapeutic procedures. In April 2019, Amgen announced that it received approval from the US Food and Drug Administration (FDA) for ‘Evenity’. The product is used for treatment of osteoporosis in women during the post-menopausal period. Amgen’s latest product approval will have a direct impact on the growth of the global market in the foreseeable future.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/osteoporosis-treatment-market-101034

Increasing Prevalence of Osteoporosis Will Provide Impetus to Market Growth

The report encompasses several factors that have contributed to the growth of the market in recent years. Among all factors, the high prevalence of osteoporosis has naturally created several growth opportunities for the companies that are currently operating in the market. Moreover, companies that weren’t initially operating in this industry have leveraged from their core business strategies, mainly due to the growing prevalence3 of the condition across the world. According to the International Osteoporosis Foundation, 25% of the  women above the age of 65 suffer from this condition. Such a high prevalence of the disease will create the platform for rapid growth.

 Large Scale Companies Are Focusing on Introduction of Novel Products

Accounting to the massive potential in the market, several large scale companies are looking to invest more in the development of newer products. Due to healthy market competition, these companies are looking to adopt standout strategies. Several companies are now focusing on introducing novel products to the market, with a bid to establishing a formidable stand. A few of the leading companies that are operating in the market include:

• AbbVie Inc.
• Eli Lilly and Company
• Amgen Inc.
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Sanofi
• Pfizer Inc.
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Others

The global osteoporosis market is segmented on the basis of: